

CLAIMS

1. Use of at least one protease inhibitor, for preparing a medicament for the
5 preventive or curative treatment of functional digestive disorders (FGID).

2. Use according to claim 1, characterized in that the protease inhibitor is an
intracolonic protease inhibitor.

10 3. Use according to either one of claims 1 or 2, characterized in that the inhibitor
is an inhibitor of serine proteases or an inhibitor of metalloproteases.

4. Use according to claim 3, characterized in that the serine protease inhibitor is
selected in the group consisting of serpin and derivatives thereof, aprotinin, N-
15 tosyl-L-phenylalanyl chloromethyl ketone, dichloroisocoumarin, nexin-1,
AEBSF-HCl, Antipain, benzamidine, leupeptin, TLCK, ovomucoid, phenylmethyl
sulfonyl fluoride, PEFABLOC® and soy bean extracts.

5. Use according to claim 3, characterized in that the metalloprotease inhibitor is
20 selected in the group consisting of amastatin, arphamenin, bestatin, diprotin A and
phosphoramidon.

6. Use according to claim 1, characterized in that the protease inhibitor is selected
in the group consisting of amprenavir, indinavir, lopinavir, ritonavir, saquinavir,
25 nelfinavir and atazanavir.

7. Use according to any one of the previous claims, for preparing a medicament
for controlling paracellular permeability of the intestinal epithelium in subjects
with functional intestinal disorders characterized by a state of hyperalgesia.

8. Use according to claim 7, for preparing a medicament for reducing the paracellular permeability of the intestinal epithelium in subjects with functional intestinal disorders characterized by a state of hyperalgesia.

5 9. Use according to any one of the previous claims, for preparing a medicament for reducing sensitivity to pain in subjects afflicted with or susceptible to functional intestinal disorders characterized by a state of hyperalgesia.

10 10. Use according to any one of claims 1 to 6, for preparing a medicament for the preventive or curative treatment of functional intestinal disorders (IFD).

15 11. Use according to claim 10, characterized in that the intestinal functional disorders are selected in the group consisting of irritable bowel syndrome (IBS), functional abdominal pain without defecation disorder and pain related to food intolerance.

12. Use according to any one of the previous claims, characterized in that the inhibitor is administered by the oral or rectal route.

20 13. Use of at least one protease inhibitor, for preparing a medicament for the preventive or curative treatment of hyperalgesia occurring in the context of intestinal pathologies.

25 14. Use according to claim 13, characterized in that the protease inhibitor is such as defined in any one of claims 2, 3, 4, 5 and 6.

30 15. Pharmaceutical product comprising at least one protease inhibitor and at least one other active agent selected in the group consisting of anticholinergic compounds, prokinetics, antidiarrheals, laxatives, modifiers of motility or visceral sensitivity, in view of a use that is combined, separate or spread out over time.

16. Product according to claim 15, characterized in that the protease inhibitor is selected in the group consisting of an inhibitor of serine proteases and an inhibitor of metalloproteases.

5

17. Pharmaceutical product according to either one of claims 15 or 16, characterized in that said product is formulated as a capsule or a gelatin capsule which releases its contents by microbial digestion in the colon.

10